Trial · NCT03822832
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 16 | Placebo Intravenous Every 4 Weeks | -12.3 | Standard Error 14.3 | Percent change | |
| Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 16 | Spesolimab 600 mg Intravenous Every 4 Weeks | -37.9 | Standard Error 9.8 | Percent change | |
| Number of Patients With Drug Related Adverse Events (AEs) | Placebo Intravenous Every 4 Weeks | Double blind treatment period | 6 | Participants | |
| Number of Patients With Drug Related Adverse Events (AEs) | Spesolimab 600 mg Intravenous Every 4 Weeks | Double blind treatment period | 4 | Participants | |
| Number of Patients With Drug Related Adverse Events (AEs) | Placebo Intravenous Every 4 Weeks | Re-allocation treatment period | 0 | Participants | |
| Number of Patients With Drug Related Adverse Events (AEs) | Spesolimab 600 mg Intravenous Every 4 Weeks | Re-allocation treatment period | 2 | Participants | |
| Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 4 | Placebo Intravenous Every 4 Weeks | -7.0 | Standard Error 3.0 | Change in score on a scale | |
| Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 4 | Spesolimab 600 mg Intravenous Every 4 Weeks | -6.3 | Standard Error 2.2 | Change in score on a scale | |
| Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Week 4 | Placebo Intravenous Every 4 Weeks | -21.6 | Standard Error 11.3 | Percent change | |
| Percentage Change From Baseline in Eczema Area and Severity Index (EASI) at Week 4 | Spesolimab 600 mg Intravenous Every 4 Weeks | -23.8 | Standard Error 8.3 | Percent change | |
| Proportion of Patients With a 50% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI50) at Week 4 and 16 | Placebo Intravenous Every 4 Weeks | Week 4 | 0.333 | Proportion of patients | |
| Proportion of Patients With a 50% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI50) at Week 4 and 16 | Spesolimab 600 mg Intravenous Every 4 Weeks | Week 4 | 0.303 | Proportion of patients | |
| Proportion of Patients With a 50% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI50) at Week 4 and 16 | Placebo Intravenous Every 4 Weeks | Week 16 | 0.056 | Proportion of patients | |
| Proportion of Patients With a 50% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI50) at Week 4 and 16 | Spesolimab 600 mg Intravenous Every 4 Weeks | Week 16 | 0.303 | Proportion of patients | |
| Proportion of Patients With a 75% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI75) at Week 4 and 16 | Placebo Intravenous Every 4 Weeks | Week 4 | 0.111 | Proportion of patients | |
| Proportion of Patients With a 75% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI75) at Week 4 and 16 | Spesolimab 600 mg Intravenous Every 4 Weeks | Week 4 | 0.091 | Proportion of patients | |
| Proportion of Patients With a 75% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI75) at Week 4 and 16 | Placebo Intravenous Every 4 Weeks | Week 16 | 0.056 | Proportion of patients | |
| Proportion of Patients With a 75% Improvement From Baseline in Eczema Area and Severity Index (EASI)(EASI75) at Week 4 and 16 | Spesolimab 600 mg Intravenous Every 4 Weeks | Week 16 | 0.152 | Proportion of patients | |
| Change From Baseline in SCORing of Atopic Dermatitis (SCORAD) at Week 4 | Placebo Intravenous Every 4 Weeks | -13.3 | Standard Error 7.0 | Change in score on a scale | |
| Change From Baseline in SCORing of Atopic Dermatitis (SCORAD) at Week 4 | Spesolimab 600 mg Intravenous Every 4 Weeks | -13.2 | Standard Error 5.2 | Change in score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03822832/results